3BartBarlogie, RobertA. Kyle, KennethC. Anderson, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase Ⅲ US Intergroup Trial S9321 J Clin Oncol, 2006, 24(6) :929-936.
4Frits van Rhee, Madhaw Dhodapkar, John D Shaughnessy Jr et al. First thalidomide clinical trial in multiple myeloma : a decade later. Blood, 2008, 112:1035-1038.
5Paul G. Richardson, Emily Blood, Constantine S. Mitsiades, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006,108 : 3458-3464.
6Paul Richardson, Sundar Jagannath, Mohamad Hussein, et al. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood, 2009,114:772- 778.
7Dominique Dubois, Ravinder Dhawan, Helgi van de Velde, et al. Descriptive and prognostic value of patient-reported outcomes : the Bortezomib experience in relapsed and refractory multiple myeloma. J Clin Oncol ,2006,24: 976-982.
8RobertZ. Orlowski, ArnonNagier, PieterSonneveld, et al. Randomized Phase Ⅲ Study of Pegylated Liposomai Doxorubiein Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma:Combination Therapy Improves Time to Progression. J Clin Oncol, 2007, 25:3892-3901.
9Paul G. Richardson, Wanling Xie, Constantine Mitsiades, et al. Single-agent Bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol , 2009,27 : 3518-3525.
10Mohamad A. Hussein. Trials of Arsenic Trioxide in Multiple Myeloma. Cancer Control, 2003, 10 : 370-374.
